The fact that tideglusib has been approved by FDA and has been tested in clinical trials of Alzheimer’s Disease, Autism Spectrum Disorder and Myotonic Dystrophy renders a potential availability also for SPG11 patients. Here, SPG11 is linked to autism spectrum disorder.